![]()  | 
	
		
 Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ 
		
		
		The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen. 
	More...  | 
| All times are GMT -7. The time now is 03:49 PM. | 
	Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
	
	Copyright HER2 Support Group 2007 - 2021